The US Food and Drug Administration (FDA) has granted Fast Track designation for Shire’s recombinant ADAMTS13 (SHP655 or previously known as BAX930) to treat acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).

The life-threatening congenital disease hTTP is caused by a deficiency in the enzyme ADAMTS13, which can cause clotting in the microvasculature with associated organ morbidities.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Shire R&D head Philip Vickers said: "As the leader in rare disease, Shire is committed to providing an innovative pipeline of world-class therapeutics to the patients that need them most.

"Today's confirmation from FDA that SHP655 for hereditary thrombotic thrombocytopenic purpura has been granted Fast Track designation reaffirms the significant unmet need that exists for this patient population and provides hope of reducing morbidity in patients with hTTP."

FDA's designation is supported by preclinical data and a Phase I study.

See Also:

"As the leader in rare disease, Shire is committed to providing an innovative pipeline of world-class therapeutics to the patients that need them most."

Data included results from 15 patients with severe hTTP who completed the multicentre study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Fast Track process has been designed to facilitate the development, and expedite the review of drugs to treat serious conditions.

Shire plans to initiate its Phase III trial with SHP655 as a randomised, open-label, two-period crossover study in a bid to evaluate its safety and efficacy to treat and prevent acute TTP events in patients with severe hereditary ADAMTS13 deficiency.

The global study will be conducted in the US, Europe, and Japan.

Between 3,000 and 4,000 patients worldwide are currently living with hTTP and there are no approved treatment options.